PMI

PHARMA SUMMIT 26

Transform & Thrive

Thursday 26th March @ Croke Park

UnitedDrug
a PHOENIX company

allphar

DRIVALIA

sn@p

LAUNCH HUB
Ignite Excellence

DAVY

PMI PHARMA SUMMIT 26
Transform & Thrive

Session 2 was proudly supported by: DAVY



Cathal Friel,
Executive Chairman

POOLBEG PHARMA

Cathal is a seasoned serial entrepreneur with a long and successful history and to date has listed five companies on the London Stock Exchange. Cathal is Managing Director of Raglan Capital and serves as Chairman and co-founder of both Poolbeg Pharma plc and European Green Transition plc. Poolbeg was established as a spin-off from hVIVO plc (formerly Open Orphan plc) in 2021, a company which Cathal also co-founded and served as Chairman until June 2025. Prior to this, Cathal co-founded Amryt Pharma plc which listed on the London Stock Exchange in 2016 and dual listed on Nasdaq in 2020 and was later sold to Chiesi Farmaceutici for $1.48bn in April 2023. Prior to that, he was co-founder and Chairman of Fastnet Oil & Gas plc, which listed on the London Stock Exchange in 2012.

Innovation in Action: Building & Scaling Success

Raglan Capital

Cathal Friel

Chairman

From Idea to Exit

What it really takes to build a successful biotech company

AMRYT PHARMA

hVIVO

Open Orphan

POOLBEG PHARMA



Raglan Capital

Building the Right Team Early

Why talent & leadership matter more than the technology

Joe Wiley
CEO

AMRYT PHARMA

Jeremy Skillington
CEO

POOLBEG PHARMA

Mo Khan
CEO

hVIVO

Scaling the Business

Moving from scientific innovation to commercial reality

Prevention of CRS by POLB 001 May Transform Cancer Immunotherapies

Potential to greatly enhance uptake and access to bispecific antibodies and CAR T therapies

Bottleneck*

~500,000 Patients

Eligible **bispecific antibody / CAR T** patients in US & EU5 for DLBCL and MM alone far exceeds treatment capacity[1]

CRS

An effective CRS preventative therapy may remove the bottleneck

>US$10B[2]

Market opportunity

1. Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023. **2.** Independent research by Decisive Consulting Limited.

*CRS prevention may contribute to bottleneck removal. Other issues, such as manufacturing, supply and other adverse events, may also present barriers to wider uptake.

Knowing When to Exit

Timing partnership, listings or acquisitions

Raglan Capital

- Amryt IPO 2016
- Nasdaq 2020
- Acquisition of Chiasma 2021
- Exit 2023



16 THE IRISH TIMES irishtimes.com

ISEQ 7,735.20 +96.54 FTSE 7,724.94 +25.45 DOW 33,517.65 -112.96 EURO £0.8811|$1.0749

Business + Your Money

Editor Ciarán Hancock Twitter @IrishTimesBiz email finance@irishtimes.com

Irish rare disease drugmaker Amryt Pharma to be sold for up to €1.4bn

EU approval secured for first treatment globally for rare genetic condition last year

DOMINIC COYLE and COLIN GLEESON

Italian rare disease specialist Chiesi Farmaceuti has agreed a €1.18 billion deal to acquire the Irish company behind a breakthrough therapy for a rare and painful skin disease that mostly affects children.

The price may rise to €1.4 billion if Amryt Pharma's Filsuvez delivers on certain targets. The drug, approved by EU medicines regulators last year, accelerates the healing process for patients with epidermolysis bullosa (EB) when their skin blisters. Though not a cure for this disease, known as "butterfly skin" disease because of the fragile nature of patients' skin that can blister at the merest touch, it is the first approved therapy for the condition.

"EB can affect every organ in the body except the brain," said Jimmy Fearon, chief executive of Debra Ireland which represents about 300 Irish patients, many of them children, who suffer from the condition. "The ... es. It is like having third-degree burns and it takes three hours a day."

The genetic condition affects about one in every 20,000 children. It causes a breakdown in the natural proteins that hold the skin together. Patients with severe forms of EB suffer from severe, chronic blistering, ulceration and scarring of the skin. They are also more prone to a form of skin cancer, infections and the risk of premature death.

Chiesi has agreed to pay $14.50 for every American depositary share (ADS) in Amryt – equivalent to $2.90 per ordinary share – which it said was a 107 per cent premium to the price the ADSs traded at last Friday, January 6th. That puts a figure of ... on the initial purchase price.

Certain milestones

The Italian company has also agreed to pay up to an additional $2.50 per ADS – 50 US cents per ordinary share – "payable if certain milestones related to Amryt's product Filsuvez are achieved". The brings the potential final price for the Irish business to $1.48 billion (€1.4 billion).

For Amryt co-founder and chief executive Joe Wiley, who holds a stake of around 2.33 per cent of the business, including vested stock that has not yet been exercised, that means a €27.5 million pay day, a figure that could rise to €32.6 million if the earnout ... that, depending on the terms of the deal, could add up to a further €6.1 million to that figure.

Other company executives share a stake of about 3.33 per cent between them, worth €39.3 million initially, and potentially up to €46.6 million.

Dr Wiley said he believed Chiesi was a good fit for the Irish business.

"Chiesi is aligned with Amryt's commitment and passion and I believe Chiesi will further maximise the value of Amryt's current portfolio and pipeline and, most importantly, will accelerate our ability to reach more patients in need globally," he said.

"The board evaluated the transaction through a thought... process that included engagement with both strategic and financial parties against Amryt's stand-alone prospects and determined that the compelling and certain cash consideration and meaningful upside presented by the CVRs [contingent value rights] provides superior risk-adjusted value relative to Amryt's stand-alone prospects.

He said he was "incredibly proud" of what Amryt had accomplished for patients, their families, healthcare professionals and shareholders in the eight years since the business was established in 2015.

Marco Vecchia, chief executive of Chiesi, said his company hoped the takeover would make Amryt's therapies available to even more patients who may require them.

Media&Marketing

Laura Slattery

Fleet Street can have their cake and eat it with Harry

It's no secret that the media likes people to talk. Entire genres of news would die were it not for the temptation or obligation people feel to reveal things that it might not, ultimately, be in their personal interest to share and that they might later come to regret.

I'm not saying that Prince Harry's disclosure he had a frostbitten penis at his brother's wedding is one of those things, but I'm also not saying it's not.

Oddly, however, if you were to consume only the British media's take on the publica...

... million people who watched distinctly unroyal drama Happy Valley on BBC One at the same time.

The figure is also considerably less than the 11.3 million who watched Oprah's 2021 interview with Meghan and Harry in the UK – a programme that was also the fifth most-watched among Irish households that year. But even if the law of diminishing returns is already in operation, a sit-down with Diana's son is not something that can just be rejected.

The memoir ...

Household medicines

Why Many Life Sciences Companies Fail Before They Scale

Raglan Capital

Regulatory hurdles

Long R&D timelines

High capital burn & adoption challenges



Why *Ireland is Attractive* for Biotech Innovators

- Strong track record of innovation in the life sciences sector
- World-class research institutions and a highly skilled talent pipeline
- Direct access to the EU market (450+ million people)
- Strategic location bridging the US and European markets
- Highly attractive environment for foreign direct investment (FDI)
- Strong government-backed support, including Enterprise Ireland
- Availability of funding through the Ireland Strategic Investment Fund (ISIF)

Raglan Capital

Advice for Innovators and Industry Leaders

- Never be afraid to try something new
- Fail early & fail often
- Life-long education process
- New businesses generally originate from a side-hussle
- Worth trying a new career direction / focus every ~5 years
- The most important thing: stop considering & just do something
- Once you learn to start a business you can do it over & over again

PMI PHARMA SUMMIT 26
Transform & Thrive

DAVY

Session 2:
Transform. Adapt. Thrive.
Lessons in Leadership & Reinvention

2026 Sponsors:

UnitedDrug
a PHOENIX company

allphar

DAVY

DRIVALIA

LAUNCH HUB
Ignite Excellence

2026 Exhibitors:

AGENCY X™
agencyx.ie

combinedmedia
DRIVING YOUR DIGITAL PRESENCE

CRYOPDP | Part of DHL Health Logistics

DRIVALIA

FORCE
RECRUITMENT | OUTSOURCING

GP CONSULT

GreenCrowd.

hubbcat®
BUSINESS CRITICAL SOLUTIONS

iNIZIO
ENGAGE

kintiga

me2you gift card

MRII
Professional Development & Networking for Healthcare Industry Representatives

nAVI GROUP

SI SALUTEM INSIGHTS

sn@p

TCP Homecare
BRING HOSPITAL CARE HOME
a PHOENIX company

uniphar

UnitedDrug
a PHOENIX company

pmi PHARMA SUMMIT 26
Transform & Thrive